Contineum Therapeutics, Inc. Class A (CTNM) has received a new Buy rating, initiated by JonesTrading analyst, Debanjana Chatterjee.
Debanjana Chatterjee has given her Buy rating due to a combination of factors surrounding Contineum Therapeutics, Inc. The company’s lead asset, PIPE-791, is positioned as a potential best-in-class treatment for idiopathic pulmonary fibrosis (IPF) due to its high receptor occupancy and slow on-rate, which may offer superior efficacy and tolerability compared to competitors. Early human data suggests a favorable safety profile, which could make PIPE-791 a leading LPA1 receptor antagonist in the market.
Additionally, the IPF market presents a significant opportunity with unmet needs that PIPE-791 could address, potentially driving substantial sales by 2037. The development of PIPE-307, in collaboration with JNJ, for relapsing-remitting multiple sclerosis (RRMS) and major depressive disorder (MDD) also adds value. Positive data expected in the second half of 2025 could enhance confidence in the company’s drug development capabilities and royalty potential. Furthermore, opportunities in progressive multiple sclerosis and chronic pain present additional upside to the company’s valuation.
Chatterjee covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals, Opthea Limited Sponsored ADR, and Sagimet Biosciences, Inc. Class A. According to TipRanks, Chatterjee has an average return of -0.3% and a 23.68% success rate on recommended stocks.